Revive Therapeutics Company Description

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders.

It develops Bucillamine, a disease-modifying anti-rheumatic drug, for the treatment of infectious diseases, including influenza and COVID-19, as well as to treat pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.

The company also develops Psilocybin, which is in Phase 1 clinical study for treating methamphetamine use disorder; and Psilocin for the treatment of depression, anxiety, bi-polar disorder, bulimia and anorexia nervosa, and other diseases.

Revive Therapeutics Ltd. is based in Toronto, Canada.

Revive Therapeutics Ltd.

Country	Canada
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	2
CEO	Michael Frank

Contact Details

Address: The Canadian Venture Building Toronto, Ontario M5C 1P1 Canada
Phone	888-901-0036
Website	revivethera.com

Stock Details

Ticker Symbol	RVV
Exchange	Canadian Securities Exchange
Fiscal Year	July - June
Reporting Currency	CAD
ISIN Number	CA7615161030
SIC Code	2836

Key Executives

Name	Position
Michael Frank	Chairman and Chief Executive Officer
Carmelo Marrelli ACIS, B.Comm., C.A., C.P.A., CGA, CPA	Chief Financial Officer
Dr. Kelly T. McKee Jr., M.D., M.P.H.	Chief Scientific Officer Consultant
Dr. Onesmo Mpanju Ph.D.	Chief Regulatory Affairs Consultant